Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Core Viewpoint - Wave Life Sciences Ltd. has announced the pricing of its public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $350 million before expenses [1][2]. Group 1: Offering Details - The public offering consists of 15,789,475 ordinary shares priced at $19.00 each, along with pre-funded warrants for 2,631,578 ordinary shares at an offering price of $18.9999 [1][2]. - The offering is expected to close on or about December 11, 2025, subject to customary closing conditions [2]. Group 2: Underwriters - Jefferies, Leerink Partners, and BofA Securities are acting as joint book-running managers for the offering, while Truist Securities and Mizuho are serving as book-runners [3]. Group 3: Company Overview - Wave Life Sciences is a biotechnology company focused on RNA medicines, utilizing its PRISM® platform to address both rare and common disorders [6]. - The company's pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [6].